FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer

The US FDA has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer. Regulatory clearance was based on findings from the double-blind, placebo-controlled Phase III HER2CLIMB-05 trial. The regimen is indicated for adults with unresectable locally advanced or metastatic HER2+ disease following induction treatment. Credit: Arif biswas/Shutterstock.com. The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer. This regimen is indicated for adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) disease following induction treatment.…

Salong Debbarma · 2026-10-08

The US FDA has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.

Source: Pharmaceutical Technology